Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Revenue of Lipella Pharmaceuticals Inc. (LIPO)
Revenue in 2023 (TTM): $449.62 K
According to Lipella Pharmaceuticals Inc.'s latest financial reports the company's current revenue (TTM) is $449.62 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lipella Pharmaceuticals Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $449.62 K | $-2,589,219 | $-4,606,432 | $-4,618,965 | $-4,618,965 |
| 2022 | $184.16 K | $-2,363,521 | $-2,588,075 | $-2,597,692 | $-2,596,059 |
| 2021 | $259.35 K | $-1,197,444 | $ | $-1,865,473 | $-1,872,203 |
| 2020 | $961.68 K | $-14,277 | $-53,691 | $-61,656 | $-66,450 |
| 2019 | $694.75 K | $11.86 K | $334 | $-61,848 | $-61,848 |